Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03635450
Recruitment Status : Recruiting
First Posted : August 17, 2018
Last Update Posted : January 4, 2019
Sponsor:
Collaborator:
The Duke Clinical and Translational Science Institute (CTSI), part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA)
Information provided by (Responsible Party):
Joanne Kurtzberg, MD, Duke University

Brief Summary:
To determine the safety of single and repeated intravenous doses of hCT-MSC in newborn infants with HIE.

Condition or disease Intervention/treatment Phase
Moderate to Severe Hypoxic-ischemic Encephalopathy Biological: Infusion of hCT-MSC Phase 1

Detailed Description:

The purpose of this study is to assess the safety of one and two intravenous infusions of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC), the first administered in the first 48 postnatal hours, and the second at two months postnatal age, in term and near term infants with moderate to severe neonatal hypoxic-ischemic encephalopathy (HIE). This is a phase I, prospective, open-label trial designed to assess the safety of one or two intravenous doses of hCT-MSC in newborn infants with moderate to severe HIE who are recipients of therapeutic hypothermia. Infants born at 36 0/7 weeks gestation or later who have moderate to severe hypoxic-ischemic encephalopathy and are receiving therapeutic hypothermia will be eligible to participate. Investigators project an accrual of 6 patients. All infants will receive intravenous infusion(s) of hCT-MSCs. The first cohort of three infants will receive a single dose in the first 48 postnatal hours. If there are no safety concerns, the second cohort of three infants will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.

The potential risks associated with infusion of MSCs include a reaction to the product (rash, shortness of breath, wheezing, difficulty breathing, hypotension, swelling around the mouth, throat or eyes, tachycardia, diaphoresis), transmission of infection, and HLA sensitization. Another risk of this study is loss of confidentiality or privacy. Every effort will be made to keep the infant's medical record confidential. The results will be summarized using descriptive statistics and statistical testing as appropriate. Continuous secondary endpoints will be summarized using mean, standard deviation, CV%, median, minimum, and maximum.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The first cohort of three patients will receive a single dose in the first 48 postnatal hours. If there are no safety concerns, the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Newborn Infants With Moderate or Severe Hypoxic- Ischemic Neonatal Encephalopathy.
Actual Study Start Date : December 27, 2018
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : March 1, 2021

Arm Intervention/treatment
Experimental: First cohort of 3 subjects enrolled
The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
Biological: Infusion of hCT-MSC
Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.

Experimental: Second cohort of 3 subjects enrolled
If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
Biological: Infusion of hCT-MSC
Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.




Primary Outcome Measures :
  1. Incidence of infusion reactions [ Time Frame: 24 hours after each infusion ]
    for this study, infusion reactions are defined as anaphylactic or anaphylactoid reactions with clinical signs inclusive of skin rashes, bronchospasm, angioedema, myocardial infarcts, arrhythmias, and acute lung injury.

  2. Incidence of Infections post-infusion [ Time Frame: Up to 2 Weeks ]
    for this study, infections recorded as safety endpoints will be defined as bacterial, viral or fungal infections identified by culture or molecular methodologies within two weeks after administration of hCT-MSC.


Secondary Outcome Measures :
  1. Survival [ Time Frame: Up to 6 months ]
    Death prior to discharge from initial hospitalization

  2. Neurodevelopmental Assessments [ Time Frame: Up to 16 postnatal months ]
    1 year (12 - 16 postnatal months) Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III) assessments in cognitive, language and motor development. Moderate to Severe CP will be assigned with cognitive score ,70, motor score ,70 and with Gross Motor Function Classification System >=2.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 48 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 36 0/7th weeks gestation or older at the time of delivery.
  • Able to receive one dose of hCT-MSCs in the first 48 postnatal hours
  • Willingness to return for one year assessments.
  • Signs of encephalopathy within 6 hours of age

Exclusion Criteria:

  • Major congenital or chromosomal abnormalities
  • Severe growth restriction (birth weight <1800 g)
  • Opinion by attending neonatologist that the study may interfere with clinical treatment or safety of subject
  • Moribund neonates for whom no further treatment is planned
  • Infants whose mothers have unknown serologies for Hepatitis B or HIV
  • Infants born to mothers are known to be HIV, Hepatitis B, Hepatitis C or who have active syphilis or CMV infection in pregnancy
  • Infants suspected of overwhelming sepsis
  • ECMO initiated or likely in the first 48 hours of life
  • Mother suspected to have intraamniotic infection at time of birth.
  • ALL blood gases (cord and postnatal) done within the first 60 minutes had a pH > 7.15 AND base deficit < 10 mEq/L (source can be arterial, venous or capillary)
  • Mother with documented Zika infection during this pregnancy
  • Availability of autologous cord blood collected and usable in the randomized trial of autologous volume- and red blood cell-reduced cord blood cells (Duke IRB Pro00066647; clinical trials.gov link: https://clinicaltrials.gov/ct2/show/NCT02612155 )

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03635450


Contacts
Layout table for location contacts
Contact: Kimberley A Fisher, PhD 919-681-4913 kimberley.fisher@duke.edu
Contact: Mandy Marion, BS 919-668-0679 mandy.marion@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27705
Contact: Kimberley Fisher, PhD    919-681-4913    kimberley.fisher@duke.edu   
Sponsors and Collaborators
Joanne Kurtzberg, MD
The Duke Clinical and Translational Science Institute (CTSI), part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA)
Investigators
Layout table for investigator information
Principal Investigator: Michael Cotten, MD Duke University

Layout table for additonal information
Responsible Party: Joanne Kurtzberg, MD, Professor Department of Pediatrics, Duke University
ClinicalTrials.gov Identifier: NCT03635450     History of Changes
Other Study ID Numbers: Pro00100253
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: January 4, 2019
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Joanne Kurtzberg, MD, Duke University:
hypoxic-ischemic encephalopathy
newborn infants
therapeutic hypothermia
hCT-MSC, an Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Product
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Brain Ischemia
Hypoxia-Ischemia, Brain
Ischemia
Hypoxia
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Hypoxia, Brain